Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in many cases. But more doctors have been using an initial, higher-than-standard dose of ...

Prior to the approval of prasugrel, clopidogrel was considered the agent of choice due to safety concerns associated with ticlopidine. A randomized controlled trial comparing prasugrel and ...

For decades, aspirin has been the standard preventive treatment for patients with blood vessel disease. After an acute ...

In TRILOGY ACS, the drug failed to surpass clopidogrel in patients who do not undergo revascularization for acute coronary syndromes. Prasugrel sales are flagging, despite the robust marketing ...

Ongoing studies of prasugrel should help determine whether this drug has a role in the initial medical management of ACS. Given the benefits of ticagrelor over clopidogrel seen in PLATO ...

Prasugrel belongs to a group of medicines ... The drug is produced by AstraZeneca. Clopidogrel, sold under the trade name Plavix among others, is an antiplatelet medication used to reduce the ...

P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...